CHRISTOPHER WELLS: Open Payments
NPI 1932665643 · WARNER ROBINS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,466 in 66 payments from 16 companies in 2025. Trend: 2023 $720 · 2024 $1,019 · 2025 $1,466
Food & beverage: $1,466
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $268 |
| Vanda Pharmaceuticals Inc. | 13 | $250 |
| Neurocrine BioSciences, Inc. | 8 | $224 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $189 |
| Alkermes, Inc. | 4 | $96 |
| ABBVIE INC. | 3 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Lundbeck LLC | 3 | $62 |
| Noven Therapeutics, LLC | 2 | $47 |
| Axsome Therapeutics, Inc. | 2 | $42 |
Products named: REXULTI, FANAPT, INGREZZA, CAPLYTA, ARISTADA, VRAYLAR, TRINTELLIX, Xelstrym.
Industry payments across GA — which companies pay providers there.
